William Barton Thesis GSK plc (NYSE:GSK) trades at low price multiples relative to competitors. At the surface, it looks like a good buy. However, in my opinion, the lower multiples reflect weaker later stage pipeline relative to competitors. Current pipeline will not face significant patent expirations over the next couple of years, but GSK needs…
Leon Neal GSK overview GSK plc (NYSE:GSK) is a British multinational “Big Pharma” established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham. It possesses a leading position in the traditional vaccine (Not mRNA vaccine) and HIV area. In fact, GSK produced the first FDA-approved malaria vaccine. Currently, its best-selling vaccine is Shingrix…
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Ireland will soon launch a compensation scheme for survivors of the country’s notorious mother and baby homes but GSK has resisted calls to contribute despite its predecessor companies testing experimental vaccines at the institutions for…
Wirestock Since I last wrote an earnings preview on pharmaceuticals company GSK plc (NYSE:GSK) last October, its price is up by 11.8%, which was to be expected on good results and the settlement of its heartburn medication, Zantac, related cases in California. With full-year 2023 results expected at the end of the month, a continued…
Extreme Media Investment Outline The returns in the healthcare industry seem to have been largely muted as more and more people flocked to tech stocks instead and other exciting high-growth industries. But this has left a vacuum and upside that needs to be filled. The share price of GSK plc (NYSE:GSK) is down 15% on…
13threephotography Since the last time I wrote about the British bio-pharma company GSK plc (NYSE:GSK) in January of this year, its price has barely moved. It has softened by under 2%. It’s year-to-date [YTD] performance is similarly underwhelming, with a 1.3% rise. This lack of price movement is a definite a call to review my…